FDA Warns L’Oreal’s Lancome Unit on Anti-Wrinkle Product Marketing

The U.S. Food and Drug Administration warned L’Oreal SA’s (OR.FR) Lancome USA unit about the marketing of certain anti-wrinkle products, saying the products are marketed with claims suggesting they are drugs. The letter discussed the marketing of several products--including Lancome’s Genifique Youth Activating Concentrate and Renergie Microlift Eye R.A.R.E. Intense Repositioning Eye Lifter--and said claims suggesting the products “boosts the activity of genes and stimulates the production of youth proteins” or provide “immediate lifting” to the eye area, violate federal drug laws.

MORE ON THIS TOPIC